The prognostic impact of PD-L1 expression on tumor-infiltrating immune cells (IC) in patients with recurrent or metastatic RCC treated with systemic therapy was previously investigated in a retrospective study, ARCHERY [8]. The gene discussed is CD274; the disease is renal cell carcinoma.